** Scientific tools maker Akoya Biosciences' AKYA.O shares fall 21.1% to $2.47 premarket
** On Thursday, co forecast 2024 rev. between $80 mln and $85 mln, lower than prior range of $96 mln to $104 mln
** Co makes products used by academics and biotechs to detect and map cell types and biomarkers, to help them understand patient response to therapy
** Since 2023, high interest rates have forced biotech companies, clients of life science firms, to cut spending
** Co posted Q3 sales of $18.8 mln, missing avg analysts' est. of $25.4 mln - LSEG
** As of last close, stock has fallen ~36% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。